ASLAN Pharmaceuticals (ASLN) Scheduled to Post Quarterly Earnings on Friday

ASLAN Pharmaceuticals (NASDAQ:ASLN) will announce its earnings results on Friday, April 26th.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its quarterly earnings data on Friday, April 12th. The company reported ($0.78) EPS for the quarter. On average, analysts expect ASLAN Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ASLAN Pharmaceuticals Stock Performance

ASLAN Pharmaceuticals stock opened at $0.47 on Thursday. The stock has a market cap of $7.68 million, a PE ratio of -0.17 and a beta of 1.45. The stock has a 50-day moving average price of $0.61 and a 200 day moving average price of $0.72. ASLAN Pharmaceuticals has a 52 week low of $0.39 and a 52 week high of $4.69.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ASLN shares. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of ASLAN Pharmaceuticals in a research report on Tuesday. Piper Sandler reissued an “overweight” rating and set a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.